Covance to Present at the Drug Information Association's 45th Annual Meeting

- Covance experts to present best practices for improving drug safety and
reducing R&D time, cost -

PRINCETON, N.J., June 16 /PRNewswire-FirstCall/ -- Covance Inc. is pleased to
announce the complete list of experts scheduled to present at the Drug
Information Association's (DIA) 45th Annual Meeting from June 21-25, 2009 in
San Diego, Calif.

The DIA Annual Meeting is the biopharmaceutical industry's largest, longest
running, global, multidisciplinary event. This year's program offers learning
opportunities for everyone and features the biggest names from industry,
regulatory, and academia.

Building on the conference theme, "Better Medicines: Improving Safety with
Every Step," Covance experts will present best practices for improving safety
while reducing the time and cost of drug development, including:

June 22, 2009:

-- "Innovation at a CRO: A Strategic Management Platform to Enhance
Overall Value of a Client's Portfolio"

10:30 a.m. | Speaker: Krish Ghosh, PhD, vice president, resource management

-- "Issues and Challenges Associated with the PSUR Process"

1:30 p.m. | Session Chair: Robert Bader, PharmD, senior director, product
safety, periapproval services

-- "Improving Safety with Expanded Training Options for Physicians in
Early Phases of Clinical Research"

1:30 p.m. | Speaker: Russ Dixon, MD, medical director, early clinical
development

-- "EDC Front to Back: Streamline Processes End-to-End for True
Operational Benefit"

3:30 p.m. | Speaker: Ross Rothmeier, senior director, EDC portfolio, clinical
development services

June 23, 2009:

-- "Corrective Action and Preventive Action Program for Clinical Trial
Programs"

8:00 a.m. | Session Chair: Bruce Wagman, MBA, RN, RAC, vice president,
regulatory affairs and quality assurance, clinical development services

-- "Routine Monitoring Visits: Pragmatic Approaches to Reduce Prep
Time by More Than 50%"

9:30 a.m. | Poster Presentation: Ann Flandermeyer, BSN, PhD, MSN, RN, project
management and clinical operations

-- "Early Exposure to the Science of Safety Through Clinical Research
in a CRO Setting for Future Medical Professionals"

9:30 a.m. | Poster Presentation: Jackie Miller-Giles, MT (ASCP), MS, global
clinical pharmacology

-- "Nonclinical Support for First-in-Human Clinical Trials"

2:00 p.m. | Speaker: Paul Baldrick, PhD, head of department, pharmaceutical
regulatory affairs

-- "Defining Quality in Clinical Trials (2nd Annual Update)"

2:00 p.m. | Session Chair: John Poland, PhD, senior director, regulatory
policy, UK, clinical development services

-- "Changes in the WHO Review of Psychoactive Substances for
International Control"

4:00 p.m. | Session Chair: Edgar Adams, ScD, MS, executive director,
epidemiology, periapproval services

-- "Site Preferences for EDC - A Comparison of European and North
American Perspectives"

4:00 p.m. | Session Chair: Eunice Franklin-Becker, MPH, senior project
manager, registries and observational studies, periapproval services

-- "First-In-Human Trial Designs: How Much is Too Much?"

4:00 p.m. | Session Chair: Mary Westrick, PhD, global vice president and
general manager, clinical pharmacology

June 24, 2009:

-- "Six Sigma: How to Leverage 'A Great Idea' in the Complex
Reality of Clinical Trials"

8:30 a.m. | Session Chair: Tim G. Strauss, MA, executive director, business
process improvement, clinical development services

-- "Outsourced Data Management: How to Align Performance
Expectations"

10:30 a.m. | Session Chair: Mark Anderson, senior director, data management,
clinical development services

-- "Site Activation: How to Get Beyond the Classic Pitfalls"

1:30 p.m. | Speaker: Heather Almonte, MBA, RAC, senior manager, site
activation, clinical development services

-- "An Overview of Challenges and Strategies to Make Remote
Investigator Training a Reality"

3:30 p.m. | Speaker: Christina Werremeyer, project manager, periapproval
services

-- "Latin America: Leveraging Regional Strengths While Proactively
Ensuring Quality"

3:30 p.m. | Session Chair: Katie Margules, PharmD, MSc, senior director,
clinical development services, Latin America

June 25, 2009:

-- "Proactive Management of Project Financials: Understand Scope of
Work, Cost to Complete, and Scope Change"

8:30 a.m. | Session Chair: Ann Flandermeyer, BSN, PhD, MSN, RN, senior
director, project management and clinical operations, clinical development
services

-- "Preserving Relationships in the Face of Divergent Project
Expansions"

8:30 a.m. | Speaker: Mike Hill, project manager, periapproval services

-- "Preclinical Safety Evaluation of Novel Adjuvants and
Vaccines"

10:30 a.m. | Session Chair: Peter Thomas, PhD, senior program manager,
strategic partnering & integrated drug development

About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies with annual
revenues greater than $1.5 billion, global operations in more than 25
countries, and more than 9,600 employees worldwide. Information on Covance's
products and services, recent press releases, and SEC filings can be obtained
through its website at www.covance.com.

About the Drug Information Association (DIA)

DIA serves more than 30,000 biopharmaceutical professionals from industry,
academia, and regulatory agencies worldwide. Through its domestic and
international meetings, training courses, workshops and webinars, DIA provides
a neutral global forum for the exchange of information critical to the
advancement of the drug discovery and lifecycle management processes.
Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland,
Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its
volunteer-based Board of Directors and executive management team. For more
information, visit www.diahome.org or call 215.442.6100.

Statements contained in this press release, which are not historical facts,
are forward-looking statements pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All such forward-looking
statements including the statements contained herein regarding anticipated
trends in the Company's business are based largely on management's
expectations and are subject to and qualified by risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include, without
limitation, competitive factors, outsourcing trends in the pharmaceutical
industry, levels of industry research and development spending, the Company's
ability to continue to attract and retain qualified personnel, the fixed price
nature of contracts or the loss of large contracts, and other factors
described in the Company's filings with the Securities and Exchange
Commission.

SOURCE Covance Inc.

Media Relations, +1-609-419-2466, or Investor Relations, +1-609-452-4807